You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Could this be the telehealth breakout Wall Street is underestimating?
Hims and Hers (HIMS -4.01%) just posted a jaw-dropping 143% stock gain and a $586 million quarter -- but Wall Street says "hold." Between booming GLP-1 sales, Food and Drug Administration (FDA) pressure, and a controversial ad blitz, the real story is anything but boring. Could this be the next massive health-tech winner?
Stock prices used were the market prices of Aug. 4, 2025. The video was published on Aug. 9, 2025.
Rick is a Wall Street Journal best-selling author with a passion for investing- namely, stock analysis and options trading. He produces content in both written and video form and chances are, you've seen his work in one of several publications, including Good Morning America, Yahoo Finance, Forbes, MSN, Business Insider, SoFi, Barchart, InvestorPlace, Seeking Alpha, Benzinga, Thrive Global and many more.
Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Stocks Mentioned
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
